























Patient-Derived Xenograft Core

Available Specimen Resources

| Organ Sites | Breast | Bladder | Gynecological | Head & Neck | Lung |
|--|---|---|--|---|---|
| Models | <ul style="list-style-type: none"> ER+ : 17 HER2+ : 10 ER+/HER2+ : 2 TNBC: 52 | <ul style="list-style-type: none"> MIBC: 7 NMIBC: 1 | <ul style="list-style-type: none"> Uterine Serous Carcinoma: 1 Ovarian Clear Cell Carcinoma: 1 | <ul style="list-style-type: none"> Larynx: 1 OC: 5 OP: 1 | <ul style="list-style-type: none"> ADC: 1 ESO: 5 Meso: 1 |
| Data Attributes | <p>Model data</p> <ul style="list-style-type: none"> WES RNAseq Proteomics Chemotherapy response <p>Patient data</p> <ul style="list-style-type: none"> Patient clinical annotations Patient-germline WES Patient-tumor omics | | | | |
| Specimens Available |  <p>Plasma</p> |  <ul style="list-style-type: none"> Vesicle composition and cargo Plasma biomarkers Circulating cell free nucleic acids  | | | |
|  <p>Fresh/Viably Frozen Tissue for Model Propagation</p> | <p>Re-establish PDX models</p>  <p>Pre-clinical in vivo studies</p>  | | | | |
|  <p>Snap Frozen Tissue</p> | <p>DNA</p>  <p>RNA</p>  <p>Protein</p>  <p>Metabolites</p>  <p>Nuclei for single cell sequencing</p>  | | | | |
|  <p>Fresh Tissue</p> | <p>Cell lines</p>  <p>Organoids</p>  <p>Tissue slices</p>  <p>Ex vivo assays</p>  | | | | |
|  <p>FFPE Slides</p> |  <ul style="list-style-type: none"> H&E Biomarker Analysis Immunostaining in situ hybridization Spatial "multi-omics"  | | | | |
|  <p>TMA Slides</p> | <p>Evaluate multiple PDX models at one time Available for Breast and Bladder models</p>  | | | | |